Volver

Bristol-Myers Squibb Company

Ticker: BMY ISIN: US1101221083
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Capitalización
117,46 MM $
P/E
16,11
Forward P/E
9,12
Profit margin
15,01%
Revenue growth QoQ
2,60%
Div. yield
4,51%
Beta
0,24
67,92 $ 0,95%
Precio a fecha de 2026-08-25 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month +8,57%
6 Months +13,21%
1 Year +50,77%
5 Years +4,59% p.a.+25,16%
10 Years +5,10% p.a.+64,41%
Since inception +4,65% p.a.+210,91%
Rendimientos por año
YTD +30,17%
2025 +0,11%
2024 +15,81%
2023 -26,14%
2022 +18,98%
2021 +2,88%

Key stats

Market cap
117,46 MM
P/E
16,11
Dividend yield
4,51%
Beta
0,24
52-week range
41.46 - 62.25
50-day MA
57,09
200-day MA
53,80
Section 1

Business overview

Company profile data from fundamentals.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 38,73%
ROA 10,69%
Profit margin 15,01%
Operating margin 33,04%
PEG ratio 1,49
Revenue/share TTM 23,82
Revenue TTM 48,48 MM
EBITDA 18,97 MM
Gross profit TTM 34,90 MM
Beta 0,24

Valuation

Trailing P/E 16,11
Forward P/E 9,12
P/B 5,85
P/S 2,42
EV/EBITDA 10,23
EV/Revenue 3,16

ESG Scores

Total ESG 29,2
Environment 3,8
Social 18,8
Governance 14,0
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 6,31
Quarterly earnings growth 9,20%
Revenue TTM 48,48 MM
Reported quarters 119
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 4,51%
Forward annual div. yield 5,62%
Dividend per share 2,5000
Payout ratio 36,85%
Ex-dividend date 2025-10-03
Next dividend date 2026-08-03
Split factor 1000000:951777
Last split date 2001-08-07
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 53,00 $
Analyst rating 3.3704

Ownership & short interest

Shares outstanding 2,04 MM
Shares float 2,03 MM
Institutional ownership 82,79%
Insider ownership 7,20%
Short ratio 3,46
Short % of float 1,94%

Details

Instrument metadata and source update timestamps.

Symbol BMY
Name Bristol-Myers Squibb Company
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US1101221083
Country USA
Code + exchange BMY.NYSE
Last price date 2026-06-26
Fundamentals updated 2026-06-29

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.